Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
Launched by H. LUNDBECK A/S · Nov 19, 2013
Trial Information
Current as of June 15, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient has PTSD, diagnosed according to DSM-IV-TR™ and confirmed by the Mini International Neuropsychiatric Interview (MINI).
- • The patient has a Clinician-Administered PTSD Scale Part 2 (CAPS-2) total score ≥70 at Screening and Baseline Visits.
- • The reported duration of the PTSD is at least 3 months.
- Exclusion Criteria:
- • The index traumatic event that led to development of PTSD took place more than 15 years before screening.
- • The patient has a severe personality disorder that in the investigator's opinion may interfere with the conduct of the study.
- • The patient is at significant suicidal risk.
- • Other inclusion and exclusion criteria may apply.
About H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampere, , Finland
Tallinn, , Estonia
Gdansk, , Poland
Helsinki, , Finland
Helsinki, , Finland
Kuopio, , Finland
Pretoria, , South Africa
Los Angeles, California, United States
Los Angeles, California, United States
Riverside, California, United States
San Diego, California, United States
San Diego, California, United States
Bradenton, Florida, United States
Gainesville, Florida, United States
Jacksonville, Florida, United States
North Miami, Florida, United States
Tampa, Florida, United States
Indianapolis, Indiana, United States
Roslindale, Massachusetts, United States
Las Vegas, Nevada, United States
Nashua, New Hampshire, United States
Bronx, New York, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Portland, Oregon, United States
Norristown, Pennsylvania, United States
Memphis, Tennessee, United States
Austin, Texas, United States
Seattle, Washington, United States
Oulu, , Finland
Turku, , Finland
Fort De France, , France
Laxou, , France
Nimes Cedex 9, , France
Thuir Cedex, , France
Tours Cedex 9, , France
Andria, , Italy
Catania, , Italy
Lecce, , Italy
Pisa, , Italy
Siena, , Italy
Bialystok, , Poland
Gdansk, , Poland
Leszno, , Poland
Lublin, , Poland
Belgrade, , Serbia
Nis, , Serbia
Novi Knezevac, , Serbia
Bloemfontein, , South Africa
Cape Town, , South Africa
Cape Town, , South Africa
Cape Town, , South Africa
Cape Town, , South Africa
Durban, , South Africa
Port Elizabeth, , South Africa
Pretoria, , South Africa
Falun, , Sweden
Stockholm, , Sweden
Uppsala, , Sweden
Patients applied
Trial Officials
Email contact via H. Lundbeck A/S
Study Director
LundbeckClinicalTrials@lundbeck.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials